Skip to main content
main-content

05.02.2018 | Pancreatic Tumors | Ausgabe 5/2018

Annals of Surgical Oncology 5/2018

Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma

Zeitschrift:
Annals of Surgical Oncology > Ausgabe 5/2018
Autoren:
MD, PhD Hiroshi Kurahara, MD, PhD Kosei Maemura, MD, PhD Yuko Mataki, MD, PhD Masahiko Sakoda, MD, PhD Satoshi Iino, MD, PhD Yota Kawasaki, MD, PhD Takaaki Arigami, MD, PhD Shinichiro Mori, MD, PhD Yuko Kijima, MD, PhD Shinichi Ueno, MD, PhD Hiroyuki Shinchi, MD, PhD Shoji Natsugoe
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1245/​s10434-018-6357-1) contains supplementary material, which is available to authorized users.

Abstract

Background

This study aimed to examine the prognostic relevance of glucose transporter type 1 (GLUT-1), which is a key regulator of the glucose metabolism. In particular, the study aimed to examine the association between GLUT-1 expression and the therapeutic effect of chemoradiotherapy (CRT) in pancreatic ductal adenocarcinoma (PDAC).

Methods

Patients with PDAC were enrolled in the study. Patients with distant metastases and those who received only chemotherapy as treatment were excluded from the study. Specimens for immunohistochemical evaluations were obtained through surgical resection and endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of the primary tumor before any treatment.

Results

This study included 197 patients. Of these 197 patients, 100 underwent upfront surgery, and 97 received neoadjuvant CRT (NACRT), which was performed mainly for patients with locally advanced tumors. Of the 97 patients who received NACRT, 21 later underwent surgical resection. For the patients who underwent upfront surgery, low GLUT-1 expression was an independent factor for a better prognosis. For the patients who underwent NACRT, low GLUT-1 expression was significantly associated with greater tumor size reduction, a higher resection rate, and a better prognosis. Additionally, GLUT-1 expression was significantly increased after NACRT treatment.

Conclusions

Among the patients with PDAC, those with low GLUT-1 expression in the primary tumor had a better prognosis those with high GLUT-1 expression. Moreover, the patients with low GLUT-1 expression displayed a better therapeutic response to NACRT.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (DOCX 15 kb)
10434_2018_6357_MOESM1_ESM.docx
Supplementary material 2 (DOCX 16 kb)
10434_2018_6357_MOESM2_ESM.docx
Supplementary material 3 (DOCX 14 kb)
10434_2018_6357_MOESM3_ESM.docx
Supplementary material 4 (DOCX 16 kb)
10434_2018_6357_MOESM4_ESM.docx
Fig. S1 Kaplan–Meier survival curves from the initial treatment (surgery) for patients who underwent upfront surgery.. Supplementary material 5 (JPEG 690 kb)
10434_2018_6357_MOESM5_ESM.jpg
Fig. S2 Kaplan–Meier survival curves from the initial treatment for patients who underwent neoadjuvant chemoradiotherapy (NACRT). a Overall survival (OS) of patients who underwent surgical resection after NACRT. b Recurrence-free survival of patients who underwent surgical resection after NACRT. c OS of patients who did not undergo surgical resection after NACRT. d Progression-free survival of patients who did not undergo surgical resection after NACRT. Supplementary material 6 (JPEG 1027 kb)
10434_2018_6357_MOESM6_ESM.jpg
Fig. S3 Kaplan–Meier survival curves from the initial treatment for patients who underwent neoadjuvant chemoradiotherapy (NACRT). Eight patients experienced a low-to-high change in glucose transporter type 1 (GLUT-1) expression due to NACRT. Supplementary material 7 (JPEG 712 kb)
10434_2018_6357_MOESM7_ESM.jpg
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 5/2018

Annals of Surgical Oncology 5/2018 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise